Aerosol Medication Use in COVID-19 Pandemic

IF 0.3 Q4 ALLERGY

Astim Allerji Immunoloji Pub Date : 2020-08-15 DOI:10.21911/aai.539

M. Topel, K. Aksu

引用次数: 0

Abstract

Administration of aerolized drugs to patients diagnosed with COVID-19 leads to the risk of transmission of patient-generated infectious aerosols to healthcare providers.While the COVID-19 pandemic is ongoing, in order to provide the best treatment for patients and at the same time to protect healthcare providers at the highest level, it is necessary to increase access to information and pay maximum attention to preventive measures.

查看原文本刊更多论文

新冠肺炎大流行期间气雾剂药物的使用

对诊断为新冠肺炎的患者使用雾化药物会导致患者产生的传染性气溶胶传播给医疗保健提供者的风险。尽管新冠肺炎疫情仍在持续，但为了为患者提供最佳治疗，同时保护最高级别的医疗保健提供者，有必要增加获取信息的机会，并最大限度地关注预防措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Astim Allerji Immunoloji ALLERGY-

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： Asthma Allergy Immunology has been published three times a year in April, August and December as the official and periodical journal of the Turkish National Society of Allergy and Clinical Immunology since 2003. All articles published in the journal have been available online since 2003. A peer reviewed system is used in evaluation of the manuscripts submitted to Asthma Allergy Immunology. The official language of the journal is English. The aim of the journal is to present advances in the field of allergic diseases and clinical immunology to the readers. In accordance with this goal, manuscripts in the format of original research, review, case report, articles about clinical and practical applications and editorials, short report and letters to the editor about allergic diseases and clinical immunology are published in the journal. The target reader population of the Asthma Allergy Immunology includes specialists and residents of allergy and clinical immunology, pulmonology, internal medicine, pediatrics, dermatology and otolaryngology as well as physicians working in other fields of medicine interested in allergy and immunological diseases.